Taguchi, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Associate Professor

Career 【 Display / hide

  • 2010.04
    -
    2011.03

    日本学術振興会特別研究員

  • 2011.04
    -
    2013.03

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013.04
    -
    2017.03

    崇城大学 , 薬学部, 助教

  • 2018.04
    -
    Present

    慶應義塾大学, 薬学部, 専任講師

Academic Background 【 Display / hide

  • 2006.03

    Kumamoto University, 薬学部

    University, Graduated

  • 2008.03

    Kumamoto University

    Graduate School, Completed, Master's course

  • 2011.03

    Kumamoto University

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士 (薬学), 熊本大学, 2011.03

Licenses and Qualifications 【 Display / hide

  • 薬剤師, 2006.04

 

Books 【 Display / hide

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017

    Scope: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

    Scope: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013

    Scope: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

    Scope: Chapter 6, pp.139-62

Papers 【 Display / hide

  • Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions

    Enoki Y., Kishi N., Sakamoto K., Uchiyama E., Hayashi Y., Suzuki N., Ito M., Taguchi K., Yokoyama Y., Kizu J., Matsumoto K.

    Drug Metabolism and Pharmacokinetics (Drug Metabolism and Pharmacokinetics)  37   100371 2021.04

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  13474367

     View Summary

    © 2020 The Japanese Society for the Study of Xenobiotics Dolutegravir (DTG) is an integrase inhibitor, whose gastrointestinal absorption is impaired by the formation of chelates with multivalent metal cation preparations. However, little is known regarding the interactions of DTG with preparations containing other multivalent metal cations or with polycation polymer preparations. This study examined how the pharmacokinetics of DTG are affected by co-administration with Al(OH)3, LaCO3, and the polycation polymers bixalomer (Bxl) and sevelamer (Svl). Prior to oral administration of DTG (5 mg/kg), rats were orally administered Al(OH)3 (150 or 300 mg/kg), LaCO3 (50 or 75 mg/kg), Bxl (250 or 500 mg/kg), or Svl (300 or 600 mg/kg). Serum concentrations of DTG were then measured over the next 24 h. Compared to the administration of DTG alone, its co-administration with Al(OH)3, LaCO3, Bxl, and Svl led to reduced serum concentration of DTG, and consequently, a significantly reduced area under the curve. These comparisons also revealed a considerable reduction in the maximum concentration, suggesting that the interactions of these agents with DTG in the intestinal tract inhibit absorption of DTG. The above results demonstrate that Al(OH)3, LaCO3, Bxl, and Svl affect the pharmacokinetics of DTG and indicate the need for caution when combining any of the above preparations with DTG.

  • The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.

    Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, Enoki Y, Taguchi K, Oda K, Fujii S, Takahashi Y, Hamada Y, Kimura T, Takesue Y, Matsumoto K

    BMC infectious diseases 21 ( 1 ) 153 2021.02

    Research paper (scientific journal), Joint Work, Accepted

  • The optimal trough-guided monitoring of vancomycin in children: Systematic review and meta-analyses.

    Moriyama H, Tsutsuura M, Kojima N, Mizukami Y, Tashiro S, Osa S, Enoki Y, Taguchi K, Oda K, Fujii S, Takahashi Y, Hamada Y, Kimura T, Takesue Y, Matsumoto K

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy  2021.02

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

  • Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model.

    Tashiro S, Hayashi M, Takemura W, Igarashi Y, Liu X, Mizukami Y, Kojima N, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K

    Pharmaceutical research (Pharmaceutical Research)   2021.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0724-8741

     View Summary

    © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature. Purpose: Although flomoxef (FMOX) has attracted substantial attention as an antibiotic against extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-producing E. coli), the pharmacokinetics/pharmacodynamics (PK/PD) characteristics of FMOX against ESBL-producing E. coli is unclear. The aim of this study was to determine the PK/PD index of FMOX against ESBL-producing E. coli. Methods: In vitro time-kill curve studies and in vivo PK/PD experiments were carried out. Results: Time–kill curves exhibited a unique bactericidal activity: time-dependent activity at low concentrations and concentration-dependent activity at high concentrations. In neutropenic murine thigh infection experiments, the antibacterial activity of FMOX correlated with the time that the free drug concentration remaining above the minimum inhibitory concentration (MIC) (fT>MIC) and the ratio of the area under the free drug concentration–time curve for a 24 h period to the MIC (fAUC24/MIC). However, the burden of ESBL producing E. coli significantly reduced when the time intervals for administration were shorter among three dosage regimens with same magnitude of fAUC24/MIC, indicating that fT>MIC is significant PK/PD index. The target value of fT>MIC for 1 log10 kill reduction was 35.1%. Conclusions: fT>MIC is the most significant PK/PD index of FMOX against ESBL-producing E. coli and its target value is ≥ 40%.

  • Possible Role of Electrolytes on the Formation of Precipitates during the Infusion of Nafamostat Mesilate in Hemodialysis.

    Yamasaki K, Nishi K, Tsukigawa K, Taguchi K, Otagiri M, Seo H

    Biological & pharmaceutical bulletin 44 ( 2 ) 259 - 265 2021

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    YAKUGAKU ZASSHI 138   1381 - 1389 2018

    Introduction and explanation (scientific journal), Single Work

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

    Introduction and explanation (scientific journal), Joint Work

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017

    Introduction and explanation (scientific journal), Joint Work

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015

    Introduction and explanation (scientific journal), Joint Work

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019.04
    -
    2021.03

    橋渡し研究戦略的推進プログラム シーズA, Other, Principal Investigator

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 田口 和明, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014.04
    -
    2017.03

    科学研究費補助金・若手研究B, Research grant, Principal Investigator

  • 一酸化炭素結合型ヘモグロビン小胞体の特発性肺線維症新規治療薬としての有用性評価

    2012.04
    -
    2014.03

    科学研究費補助金・若手研究B, Research grant, Principal Investigator

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Application No.: 特願2020-144044  2020.08 

    Patent, Joint, National application

  • 横紋筋融解症治療剤

    Registration No.: 特許第6523842号  2019.05

    Patent, Joint, National application

Awards 【 Display / hide

  • 熊本大学学長賞

    2011.03

  • 日本薬学会九州支部学術奨励賞

    2017.12

  • 日本薬学会奨励賞

    2020.03

    Type of Award: Awards of National Conference, Council and Symposium

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2021

  • SEMINAR (PHARMACODYNAMICS)

    2021

  • RESEARCH FOR BACHELOR'S THESIS 1

    2021

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2021

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2021

display all >>